Navigation Links
Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
Date:6/30/2011

CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, and MM-398, a nanoliposomal encapsulation of irinotecan, at the 14th World Conference on Lung Cancer, taking place July 3 – 7, 2011, in Amsterdam, The Netherlands.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-151MM-151 is designed to effectively block downstream signaling of the EGFR receptor, a key oncogene in various carcinomas. The poster will present pre-clinical data regarding the potency of MM-151 compared to existing monoclonal therapies targeting EGFR.Poster #3656 presents preclinical data on the ability of  MM-151 to effectively block EGFR pathway activation in in-vitro signaling and inhibit tumor cell growth in-vitro and in-vivo in lung cancer modelsPoster Session:  P2.070: Poster Session 2

Number:  3656

Date/Time:  Tuesday, July 5, from 12:15 PM – 2:00 PM

Location:  RAI Exhibition and Convention Centre, Exhibition HallMM-398  

MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors.  MM-398, in partnership with PharmaEngine, Inc., is in clinical development in colorectal, gastric and pancreatic cancer and in glioma.  The poster will present preclinical data on the safety and activity of MM-398 in lung cancer xenograft models.Poster #S420-421 presents preclinical data on MM-398's safety and activity Oral Session:  033.03: Preclinical Models 1

Number:  S420-421

Date/Time:  Wednesday, July 6, from 2:30 PM – 4:00 PM

Location:  Room D201Ab
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
2. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
3. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
4. Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
6. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
7. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
8. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
9. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
11. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  Peter Walter wurde als Gewinner ... seine bahnbrechende Arbeit ausgewählt, die sich damit ... sowie für die Entschlüsselung der Komponenten eines ... nutzen, der mit der Ansammlung von deformierten ... Biochemie an der University of California, San ...
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
(Date:3/27/2015)... Md. , March 27, 2015  CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... three and 12 months ended December 31, 2014.  ... ($1.6 million), or ($0.05) per share, for the three ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... WALTHAM, Mass., Feb. 13 Inverness Medical,Innovations (Amex: ... announced,acquisition of BBI Holdings Plc was successfully completed ... Kingdom, specializes in the development,and manufacture of non-invasive ... for manufacturing superior quality gold reagents. The,final purchase ...
... Feb. 13 The following statement,is attributable to ... in,Infection Control and Epidemiology (APIC):, "APIC is ... -- as high as 70 percent according to ... pUSA03-positive strain, provide evidence that,the very nature of ...
... Mich., Feb. 13 Neogen Corporation,(Nasdaq: NEOG ... for the dairy,industry to include the quickest test ... of dairy antibiotics is used to treat,bovine mastitis, ... TetraStar(R) dairy antibiotic test for tetracyclines,complements the company,s ...
Cached Biology Technology:APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs) 2Neogen Launches Quickest Test Available for Tetracyclines in Milk 2
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
(Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Iris Biometrics - Global Strategic Business Report" ... worldwide markets for Iris Biometrics in US$ Thousands. The report ... , Japan , Europe ... East , and Latin America . ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... In today,s world, we simply cannot do without lasers. We ... weld, cut, or bend car components, survey roads, monitor our ... from the Fraunhofer Institute for Applied Solid State Physics IAF ... Their quantum cascade laser a particular type of infrared ...
... 2013 -- Research!America,s 18th annual Advocacy Awards will honor ... distinguished in their commitment to advancing medicine and health. ... 2014, at the Andrew W. Mellon Auditorium in Washington, ... The 2014 Advocacy Award winners are actress Glenn ...
... Bizkaia, Bilbao Chemicals (Barakaldo 1947-1987) and Nexana (Erandio 1952-1982), ... environment with no control whatsoever. Today we have become ... by this dumping and the difficulty in achieving this ... destroy the lindane mixed with the soil. A study ...
Cached Biology News:Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3Research!America honors leaders in medical and health research advocacy 2Research!America honors leaders in medical and health research advocacy 3Research!America honors leaders in medical and health research advocacy 4A fresh solution for the lindane problem 2A fresh solution for the lindane problem 3
Bovine Calf Serum...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
NEWBORN CALF SERUM AND PLASMA...
NEWBORN CALF SERUM AND PLASMA...
Biology Products: